BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Oisin Biotechnologies

Oisin Biotechnologies logo

Founded
2014
Patents
3

Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age related diseases.

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Oisín Biotechnologies is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.*


Posts Mentioning This Company

15 Biopharma Research Trends to Watch in 2022

  
Table of contents:    mRNA vaccines and RNA therapies  Epitranscriptomics Targeting RNA with small molecules Deep learning and big data in drug discovery Neoantigens Theranostics  Exosomes Synthetic Biology 3D Bioprinting Antibiotics “anti-trend” (and hope?) Nanotechnologies in Drug Delivery Gene Editing (CRISPR-Cas9) Aging research  Microbiome  Protein Degraders   Discoveries made in …
SHARE